Medtronic, the global medical-device powerhouse that has been part of Santa Rosa’s business fabric for nearly thirty years, is preparing to shut down operations at its Fountaingrove campus and head out of town. The company told employees yesterday that it will gradually exit the site in a staged pullout set to wrap up in spring 2028, a move that puts about 370 local jobs at risk. Leadership has described the decision to employees as difficult but strategic, and said some positions will start shifting out as soon as next spring. The move effectively closes the book on almost three decades of cardiovascular work in the city and could significantly reorder Sonoma County’s advanced-manufacturing scene.
What Exactly Medtronic Is Shutting Down
According to The Press Democrat, roughly 370 employees in Santa Rosa were formally notified Thursday that Medtronic plans to relocate their work primarily to Mounds View, Minnesota, and Galway, Ireland. The company intends to wind down activity at its two-building Fountaingrove complex at 3540 and 3576 Unocal Place in phases, rather than in a single cut. The newspaper reports that some roles are scheduled to begin moving out next spring, with the final stage of the transition targeted for spring 2028.
A Global Giant Rewrites Its Map
Medtronic reported fiscal-year 2025 revenue of about $33.5 billion, with its coronary and peripheral vascular business bringing in roughly $2.5 billion last year, as detailed by Medtronic. Those numbers underscore just how large the company’s overall operation is compared with a single regional site. Against that backdrop, Medtronic is consolidating work into bigger hubs while still maintaining a global footprint, even if Santa Rosa now finds itself on the wrong side of that corporate map.
Local Backdrop: County Real Estate Shuffle
The timing of Medtronic’s decision hits as Sonoma County is already rethinking where it houses its own employees. County records show the Board of Supervisors signed off in 2025 on a $32 million purchase of two buildings on Brickway Boulevard as part of an ongoing County Government Center plan. Those decisions, recorded in official county documents, mean local officials now have a set of newly acquired properties to keep in mind as they respond to potential job losses and broader economic ripples from Medtronic’s slow-motion exit.
Santa Rosa’s Stent-Built Legacy
Medtronic’s deep roots in Santa Rosa trace back to Arterial Vascular Engineering, a local stent maker the company acquired in 1998 for roughly $3.7 billion. That deal turned the city into a national hub for coronary devices almost overnight. Over the years, the Fountaingrove campus expanded into a mix of research, development and manufacturing operations that became a key pillar of Sonoma County’s advanced-manufacturing cluster. The pending closure marks a sharp turn for a site that once symbolized the region’s rise in high-tech medical hardware.
What Comes Next For Workers And The Campus
Medtronic told The Press Democrat that it will wind down the Santa Rosa operation in stages and provide transition support as positions are moved to other locations or eliminated. The Santa Rosa addresses remain listed on Medtronic’s locations page, and the facility at 3576 Unocal Place appears in federal records, aligning with the sites identified in local coverage and confirming that they are still active while the company prepares its exit. County and business leaders have said they will review the fallout at upcoming public meetings and look at options to assist workers who lose their jobs.
For now, the multiyear schedule, with some roles leaving next spring and the last phase planned for spring 2028, offers employees and local officials a bit of runway to plan. It also raises immediate questions about how Sonoma County will replace the lost payroll and keep its specialized medical-device talent from drifting away. Expect supervisors and economic development groups to scrutinize Medtronic’s move closely at the next round of county hearings and workforce forums, as the community starts grappling with what a post-Medtronic future looks like.
